# Anlotinib

Source: https://onco.cc/drugs/anlotinib/  
OnCo record `anlotinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Anlotinib is one of the most used cancer pills in China, first approved for lung cancer after other treatments have failed and then for several rarer tumours.

## Summary

Developed by Chia Tai Tianqing (Sino Biopharm); approved by the NMPA in May 2018 for advanced NSCLC after at least two lines on ALTER 0303 (439 patients: median overall survival 9.6 versus 6.3 months with placebo, hazard ratio 0.68), then for soft tissue sarcoma (2019), small cell lung cancer after two lines (2019) and medullary thyroid cancer (2020), with a string of combination trials alongside domestic PD-1 antibodies. Its wide use reflects NRDL listing from 2018 and a large domestic sales force as much as its effect size.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Also known as: Catequentinib; Qezzaqar
- Tags: china
- Brand: Focus V
- Code: AL3818
- Modality: Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)
- Mechanism: Oral inhibitor of VEGFR1-3, FGFR1-4, PDGFR alpha and beta, and KIT, blocking angiogenesis and tumour cell proliferation.
- Approvals: China 2018: Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303); China 2019: Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines; China 2020: Advanced medullary thyroid cancer

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Anlotinib
- Sino Biopharmaceutical / Chia Tai Tianqing (archived copy): https://web.archive.org/web/20251122085435/https://www.sinobiopharm.com/en/
- ALTER 0303 (JAMA Oncol 2018): https://doi.org/10.1001/jamaoncol.2018.3039
- NMPA (National Medical Products Administration): https://www.nmpa.gov.cn

## Connected records

- cancers: [Alveolar soft part sarcoma](https://onco.cc/cancers/alveolar-soft-part-sarcoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/), [KIT](https://onco.cc/targets/kit/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/), [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- pathways: [VEGF angiogenesis](https://onco.cc/pathways/vegf-angiogenesis/)
- trials: [A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients](https://onco.cc/trials/nct06469879/), [A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer](https://onco.cc/trials/nct05913089/), [A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC](https://onco.cc/trials/nct07562581/), [A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC](https://onco.cc/trials/nct07815223/), [A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W](https://onco.cc/trials/nct06048315/), [A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for](https://onco.cc/trials/nct07728955/), [A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can](https://onco.cc/trials/nct04854668/), [A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07538271/), [ALTER 0303](https://onco.cc/trials/alter-0303/), [Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer](https://onco.cc/trials/nct07398326/), [Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.](https://onco.cc/trials/nct05862337/), [Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer](https://onco.cc/trials/nct04322617/), [Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment](https://onco.cc/trials/nct06662877/), [Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.](https://onco.cc/trials/nct07443397/), [Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07635290/), [Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct06901622/), [Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy](https://onco.cc/trials/nct06992336/), [Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms](https://onco.cc/trials/nct06767813/), [Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma](https://onco.cc/trials/nct07548177/), [mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer](https://onco.cc/trials/nct06761027/), [Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A](https://onco.cc/trials/nct04846634/), [Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)](https://onco.cc/trials/nct03016819/), [QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer](https://onco.cc/trials/nct07636226/), [QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride](https://onco.cc/trials/nct07601178/), [Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)](https://onco.cc/trials/nct07501169/), [Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer](https://onco.cc/trials/nct07139470/), [Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07025174/), [Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell](https://onco.cc/trials/nct06441344/), [Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC](https://onco.cc/trials/nct06456138/)
- people: [Ying Cheng](https://onco.cc/people/cheng-ying/)
- drugs: [Cediranib](https://onco.cc/drugs/cediranib/)

---
JSON: https://onco.cc/api/v1/entities/anlotinib.json